WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 1, 2016--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for
atrial fibrillation (Afib) and left atrial appendage management, will
release its financial results for the fourth quarter and full year 2015
on Tuesday, February 23, 2016.
AtriCure will host a conference call at 4:30 p.m. Eastern Time on
Tuesday, February 23, 2016 to discuss its fourth quarter and full year
2015 financial results. A live webcast of the conference call will be
available online on the Investor page of AtriCure’s corporate website at www.atricure.com.
You may also access this call through an operator by calling (855)
307-9214 for domestic callers and (330) 863-3275 for international
callers using conference ID number 42156030.
The webcast will be available on AtriCure’s website and a telephonic
replay of the call will be available through March 1, 2016. The replay
dial-in numbers are (855) 859-2056 for domestic callers and (404)
537-3406 for international callers. The conference ID number is 42156030.
About AtriCure, Inc.
AtriCure, Inc. is a medical device company providing innovative atrial
fibrillation (Afib) solutions designed to produce superior outcomes that
reduce the economic and social burden of atrial fibrillation. AtriCure’s
Synergy™ Ablation System is the first and only surgical device approved
for the treatment of persistent and longstanding persistent forms of
Afib in patients undergoing certain open concomitant procedures.
AtriCure’s AtriClip™ left atrial appendage management (LAAM) exclusion
device is the most widely sold device worldwide that’s indicated for the
occlusion of the left atrial appendage. The company believes
cardiothoracic surgeons are adopting its ablation and LAAM devices for
the treatment of Afib and reduction of Afib related complications such
as stroke. AtriCure recently acquired nContact, a leader in minimally
invasive technology for epicardial ablation. nContact’s mission is to
transform the underserved arrhythmia population through a
multidisciplinary epicardial-endocardial ablation approach. Afib affects
more than 33 million people worldwide. For more information visit AtriCure.com
or follow us on Twitter @AtriCure.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160201005865/en/
Source: AtriCure, Inc.
Andy Wade, Senior Vice President and Chief
Financial Officer, 513-755-4564